摘要:
This invention provides a method of treating or inhibiting cardiovascular, cerebral vascular, or peripheral vascular disease in a mammal in need thereof, which comprises providing said mammal with an effective amount of a rapamycin.
摘要:
A compound of the formula 1 or the pharmaceutically acceptable salt thereof; wherein a, c, d, k, l, m, W, X, Y Z, R1, and R4 are as defined, and useful to treat inflammation and other immune disorders.
摘要:
This invention is directed to 3-(diarylmethylene)-8-azabicyclonull3.2.1nulloctane derivatives useful as null-opioid or null-opioid receptor modulators. Depending on their agonist or antagonist effect, the compounds are useful analgesics, immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases.
摘要:
The present invention relates to 8-azabicyclonull3.2.1nulloct-2-ene derivatives in their labelled form. Furthermore, the present invention relates to the use of said derivatives in their labelled or unlabelled form in diagnostic methods, in particular for in vivo receptor imaging (neuroimaging).
摘要:
A method for treating sexual dysfunction in a patient taking anti-depressant medication in need of such treatment comprising administering a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt thereof to said patient is disclosed. The method may be utilized for patients taking anti-depressants such as tricyclic anti-depressants, monamine oxidase inhibitors or serotonin selective reuptake inhibitors.
摘要:
The invention provides compounds of Formula I: 1 These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which cc7 is known to be involved.
摘要:
Compounds of the formula 1 and their pharmaceutically acceptable salts, wherein R1, R2, R3 and n are defined as in the specification, intermediates in the synthesis of such compounds, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of neurological and psychological disorders are claimed.
摘要:
Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines of general formula 1: 1 wherein: R1 and R2, which are identical or different, are each hydrogen, C1-C6-alkyl, C1-C6-alkyloxy, OH, F, Cl, or Br; R3 is hydrogen, F, Cl, Br, methyl, ethyl, OH, or methoxy; R4 and R5, which are identical or different, are each hydrogen, methyl, or ethyl; R6 is hydrogen; X is NH2, NHnull(C1-C6-alkyl), N(C1-C6-alkyl)2, the two C1-C6-alkyl groups of which are identical or different, NHnullCOH, NHnullCO(C1-C6-alkyl), or F; A is null(CH2)3null, nullCH2nullCH2nullOnull, nullCH2nullOnullCH2null, null(CH2)4null, nullCH(C1-C6-allyl)nullOnullCH2null, null(CH2)2nullOnullCH2null, null(CH2)3nullOnull, null(CH2)5null, nullCH2nullOnull(CH2)3null, null(CH2)2nullOnull(CH2)2null, null(CH2)3nullOnullCH2null, null(CH2)4nullOnull, nullCH2nullOnullCH2nullCH2nullOnull, 2 the racemates thereof, the enantiomers thereof, the diastereomers thereof, and mixtures thereof, and the pharmacologically acceptable acid addition salts thereof, processes for preparing them, and their use as pharmaceutical compositions.
摘要:
The invention provides compounds of Formula I: 1 These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which null7 is known to be involved.